SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hui Wang, Fangxia Guan, Di Chen, Qing Ping Dou, Huanjie Yang, An analysis of the safety profile of proteasome inhibitors for treating various cancers, Expert Opinion on Drug Safety, 2014, 13, 8, 1043

    CrossRef

  2. 2
    Ki-Seong Eom, Seok Jin Kim, Je-Jung Lee, Cheolwon Suh, Jin Seok Kim, Sung-Soo Yoon, Byung Soo Kim, Hye Jin Kang, Young Jin Choi, Chul Soo Kim, Yang Soo Kim, Jae-Yong Kwak, Yoo Jin Kim, Young Don Joo, Yeung-Chul Mun, Deog Yeon Jo, Joon Seong Park, Chi-Young Park, Sung-Hyun Kim, Chang-Ki Min, Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study, BioMed Research International, 2014, 2014, 1

    CrossRef

  3. 3
    Michael Byrne, Joseph Katz, Jan Moreb, Cancer Biomarkers, 2014,

    CrossRef

  4. 4
    Maurizio Zangari, Evangelos Terpos, Fenghuang Zhan, Guido Tricot, Impact of bortezomib on bone health in myeloma: A review of current evidence, Cancer Treatment Reviews, 2012, 38, 8, 968

    CrossRef

  5. 5
    Maurizio Zangari, Monette Aujay, Fenghuang Zhan, Kristina L. Hetherington, Tamara Berno, Ravi Vij, Sundar Jagannath, David Siegel, A. Keith Stewart, Luhua Wang, Robert Z. Orlowski, Andrew Belch, Andrzej Jakubowiak, George Somlo, Suzanne Trudel, Nizar Bahlis, Sagar Lonial, Seema Singhal, Vishal Kukreti, Guido Tricot, Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients, European Journal of Haematology, 2011, 86, 6
  6. 6
    Robert Coleman, Luis Costa, Fred Saad, Richard Cook, Peyman Hadji, Evangelos Terpos, Patrick Garnero, Janet Brown, Jean-Jacques Body, Matthew Smith, Ker-Ai Lee, Pierre Major, Meletios Dimopoulos, Allan Lipton, Consensus on the utility of bone markers in the malignant bone disease setting, Critical Reviews in Oncology/Hematology, 2011, 80, 3, 411

    CrossRef

  7. 7
    Michel Delforge, Evangelos Terpos, Paul G. Richardson, Ofer Shpilberg, Nuriet K. Khuageva, Rudolf Schlag, Meletios A. Dimopoulos, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Olga S. Samoilova, Maria-Victoria Mateos, Hila Magen-Nativ, Hartmut Goldschmidt, Dixie-Lee Esseltine, Deborah S. Ricci, Kevin Liu, William Deraedt, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel, Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma, European Journal of Haematology, 2011, 86, 5
  8. 8
    Shmuel Yaccoby, Advances in the understanding of myeloma bone disease and tumour growth, British Journal of Haematology, 2010, 149, 3
  9. 9
    Maurizio Zangari, Fenghuang Zhan, Guido Tricot, Bone and paraproteinemias, Current Opinion in Supportive and Palliative Care, 2010, 4, 3, 195

    CrossRef

  10. 10
    Monica De Matteo, Anna Elisabetta Brunetti, Eugenio Maiorano, Paola Cafforio, Franco Dammacco, Franco Silvestris, Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide, Leukemia Research, 2010, 34, 2, 243

    CrossRef

  11. 11
    Shmuel Yaccoby, Osteoblastogenesis and tumor growth in myeloma, Leukemia & Lymphoma, 2010, 51, 2, 213

    CrossRef

  12. 12
    G. David Roodman, Targeting the bone microenvironment in multiple myeloma, Journal of Bone and Mineral Metabolism, 2010, 28, 3, 244

    CrossRef

  13. 13
    T. B. Bartel, J. Haessler, T. L. Y. Brown, J. D. Shaughnessy, F. van Rhee, E. Anaissie, T. Alpe, E. Angtuaco, R. Walker, J. Epstein, J. Crowley, B. Barlogie, F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, 2009, 114, 10, 2068

    CrossRef

  14. 14
    J J Shah, R Z Orlowski, Proteasome inhibitors in the treatment of multiple myeloma, Leukemia, 2009, 23, 11, 1964

    CrossRef

  15. 15
    E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, M.-A. Dimopoulos, T. Facon, M. Macro, A. Waage, P. Sonneveld, The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network, Annals of Oncology, 2009, 20, 8, 1303

    CrossRef

  16. 16
    Current Awareness in Hematological Oncology, Hematological Oncology, 2008, 26, 2
  17. 17
    G. D. Roodman, Skeletal Imaging and Management of Bone Disease, Hematology, 2008, 2008, 1, 313

    CrossRef

  18. 18
    Angela M. Davies, Cheryl Ho, Alex S. Metzger, Laurel A. Beckett, Scott Christensen, Michael Tanaka, Primo N. Lara, Derick H. Lau, David R. Gandara, Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer, Journal of Thoracic Oncology, 2007, 2, 12, 1112

    CrossRef